Drugs / Rifamycin SV MMX
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT04026984 | Jun 2024 → Jun 2025 | acute diarrhea | RedHill Biopharma Limited | Unknown | No outcome recorded |
| Phase 2 | NCT04501380 | Jun 2020 → Dec 2022 | small intestinal bacterial overgrowth | Bradley Connor | Unknown | No outcome recorded |
| Phase 2 | NCT04082780 | Sep 2019 → Apr 2023 | cirrhosis of liver, hepatic encephalopathy | Hunter Holmes Mcguire Veteran Affairs Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01847664 | Aug 2013 → Jul 2017 | diverticulitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01208922 | Nov 2010 → Jan 2016 | acute diarrhea | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01142089 | May 2010 → Jun 2012 | acute diarrhea | Cosmo Technologies Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifamycin SV-MMX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01847664 ↗ |
| Known as | AEMCOLO | “We evaluated the use of another ansamycin antibiotic, rifamycin SV MMX (AEMCOLO) in the treatment of SIBO.” PMID 40181268 ↗ Apr 2025 |
| Route | Oral | “Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).” NCT01142089 ↗ |